Navigation Links
Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
Date:9/23/2009

SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated significantly better outcomes in key safety and efficacy measures compared to the TAXUS(R) Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS). At one year, XIENCE V demonstrated a significantly lower incidence of major adverse cardiac events (MACE) compared to TAXUS (6.2% XIENCE V vs. 9.1% TAXUS, p-value= 0.023) in the trial's primary endpoint, which is a composite of all death, non-fatal heart attack (myocardial infarction) and target vessel revascularization (TVR). Additionally, XIENCE V demonstrated a significantly lower rate of stent thrombosis compared to TAXUS (0.7% XIENCE V vs. 2.6% TAXUS, p-value=0.002), a significantly lower rate of TVR (2.4% XIENCE V vs. 6.0% TAXUS, p-value=0.0001), and a significantly lower rate of TLR (1.7% XIENCE V vs. 4.8% TAXUS, p-value=0.0002).

The results from the COMPARE trial were presented by Peter Smits, M.D., of Maasstad Ziekenhuis, Rotterdam, the Netherlands, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

"The COMPARE trial, which studied a real-world, complex patient population, reaffirms what we saw in SPIRIT IV earlier today and what we've seen throughout our SPIRIT family of trials - with XIENCE V showing consistent, outstanding performance compared to TAXUS, whether it's TAXUS Express in SPIRIT IV or now TAXUS Liberte in the investigator-initiated study COMPARE," said John Capek, Ph.D., executive vice president, Medical Devices, Abbott.

About XIENCE V

XIENCE V is used to treat coronary artery disease by propping ope
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
2. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
5. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
6. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
9. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
10. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
11. MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Click here for additional information on ... DPLO ), the nation,s largest independent specialty pharmacy, ... 31, 2014. All comparisons, unless otherwise noted, are to the ... Fourth Quarter 2014 Highlights include: , Revenue of ... dispensed of 208,000, an increase of 11% , Gross ...
(Date:3/2/2015)... , March 2, 2015  Vivex Biomedical, Inc., a ... and biocellular products, announced today that it hired ... of UMTB Biomedical, Inc.   Vivex Biomedical formed UMTB Biomedical ... Miami Tissue Bank (UMTB) in November 2014. UMTB is ... Mr. Barnes is a twenty-five year veteran of the ...
(Date:3/2/2015)... March 2, 2015  Champions Oncology, Inc. (OTC-PINK: CSBR), ... solutions and services to personalize the development and use ... on the $2 million convertible promissory notes with two ... Dr. David Sidransky , chairman ... benefit from the confidence and commitment of our two ...
Breaking Medicine Technology:Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 2Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 3Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 4Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 5Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 6Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 7Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 8Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 9Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 10Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 11Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 12Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 13Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 14Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 15Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 16Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 17Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 18Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 19Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 20Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 21Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 2Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 3Champions Oncology Extends Convertible Debt Financing 2Champions Oncology Extends Convertible Debt Financing 3
(Date:3/2/2015)... March 02, 2015 “ Wants and ... its monthly AppWatch, which features the latest and coolest ... Andrew Tropeano, a mobile technology expert and host of ... how this app helps people evaluate priorities. , Whether ... the Wants and Needs app. The app allows people ...
(Date:3/2/2015)... Raleigh, NC (PRWEB) March 02, 2015 ... response can be a better predictor of outcomes for ... here to read details of the new study ... and pathologists at the University of Eastern Piedmont followed ... underwent talc pleurodesis treatment for excess lung fluid. ...
(Date:3/2/2015)... Alabama (PRWEB) March 02, 2015 Robins ... - In conjunction with Women in Construction Week (March ... Construction, or NAWIC) and National Women’s History Month, Robins ... commitment positively affect the company and the construction industry ... management team, to the dozens of roles in between, ...
(Date:3/2/2015)... York (PRWEB) March 02, 2015 ... at Recovery Unplugged™—will be delivering a plenary address ... Perspective on the Art of Healing and Recovery ... (NCAD) and Behavioral Healthcare Executive Summit (BHES).     , ... Mr. Supa’s songs have been recorded by some ...
(Date:3/2/2015)... Mountain View, CA (PRWEB) March 02, 2015 ... announced today that it has officially launched a ... Bo Gustafsson, head of product development for BNatrl, ... developed through feedback from Olympic and other world-class ... I'm excited to use this pure whole food ...
Breaking Medicine News(10 mins):Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Robins & Morton Recognizes Women In Construction 2Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Bnatrl Launches Multivitamin Supplement for Runners 2
... Start-up FundingMINNEAPOLIS, May 4 CoreSpine Technologies, a ... received 510(k) clearance to market from the U.S. ... Nucleus Removal System. "The clearance of the ... CoreSpine," said Christine Horton, Chief Executive Officer of ...
... wellness & HR summit for organizations in SE ... decision makers and HR professionals. Increase wellness, decrease ... productivity. TROY, Mich., May 4 Cambridge Employee ... host its fourth annual corporate Wellness & HR ...
... Group, a life science-focused strategic communications agency, announced today ... sciences agency client roster.Donna L. LaVoie, President & CEO ... working on the leading edge of the life sciences ... therapeutics for complex central nervous system disorders, Mithridion,s strategy ...
... Information from American Red CrossCHICAGO, May 4 As ... to the swine flu (H1N1 flu outbreak), millions of ... caregiver options. In response to this recent flu ... to Sittercity.com for the month of May. With ...
... members and 18 foreign associates from 15 countries elected recently to the ... ... CA (Vocus) May 4, 2009 -- Five UCSF faculty scientists ... countries elected recently to the National Academy of Sciences, the Academy has ...
... attention to urgency in preventing stroke and supporting 6 million stroke survivors ... ... year nearly 795,000 people will have a stroke, leaving a path of ... National Stroke Association , which is observing National Stroke Awareness Month ...
Cached Medicine News:Health News:CoreSpine Technologies(TM) Receives Clearance to Market Surgical Disc Preparation Device 2Health News:Cambridge Employee Benefits to Host Corporate Wellness & HR Summit 2Health News:LaVoie Group Appointed by Mithridion as PR Agency 2Health News:In-Home Caregivers Standing by Nationwide to Support Increased Need Due to Swine Flu 2Health News:Five UCSF Scientists Elected to National Academy of Sciences 2Health News:Five UCSF Scientists Elected to National Academy of Sciences 3Health News:Five UCSF Scientists Elected to National Academy of Sciences 4Health News:Five UCSF Scientists Elected to National Academy of Sciences 5Health News:Five UCSF Scientists Elected to National Academy of Sciences 6Health News:Five UCSF Scientists Elected to National Academy of Sciences 7Health News:Five UCSF Scientists Elected to National Academy of Sciences 8Health News:Four of Five Families Will Be Touched by Stroke in 2009 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: